Naar topnavigatiemenu Naar hoofdnavigatiemenu Naar hoofdinhoud
Profile picture of Ron Fouchier
Principal Investigator

R.A.M. (Ron) Fouchier, Professor

Deputy Head of the Erasmus MC department of Viroscience

Deputy Head of the Erasmus MC department of Viroscience

  • Department
  • Viroscience
  • Focus area
  • Molecular virology
Contact  

About

Introduction

I received a PhD in Medicine from University of Amsterdam in 1995 for studies on HIV and continued to study HIV as a post-doctoral fellow at the Howard Hughes Medical Institute, University of Pennsylvania School of Medicine in Philadelphia, from 1995-1998.

I subsequently started a new group to study the molecular biology of respiratory viruses, in particular influenza A virus, at the Viroscience Department of Erasmus MC Rotterdam. As a fellow of the Royal Dutch Academy of Sciences, I studied influenza virus zoonoses and pathogenicity. Achievements of my team include the identification and characterization of several "new" viruses; the human metapneumovirus (hMPV), human coronavirus NL63, the SARS coronavirus (SARS-CoV), the MERS coronavirus (MERS-CoV), and a new influenza A virus subtype (H16).  I am alumni member of the "Young Academy" of the Royal Dutch Academy of Sciences, elected member of the Royal Dutch Academy of Sciences, member of the Royal Holland Society of Sciences and Humanities, recipient of the 2006 Heine-Medin award of the European Society for Clinical Virology and the 2013 Huibregtsen prize for top innovative science with societal impact. I co-authored more than 350 publications that have been cited ~30,000 times. I am an editor for several infectious disease journals, and member of advisory committees for Dutch government and (international) scientific organisations and conferences. My group is part of an NIH/NIAID Center of Excellence for Influenza Research, and participates in several WHO working groups.

My research is further funded by several EU programs and Dutch and US government.

Field(s) of expertise

Molecular Virology and Virus Evolution

Education and career

  • 1990 - 1995:     
    PhD medicine. University of Amsterdam, The Netherlands. Thesis: Molecular determinants of HIV-1 phenotype
  • 1984 - 1988:     
    BSc Microbiology. State College of Agriculture, Wageningen, The Netherlands


  • 2007 - present: 
    Professor, Molecular Virology, Erasmus MC, Rotterdam, NL
  • 2006 - 2007:     
    Associate professor, Molecular Virology, Erasmus MC, Rotterdam, NL
  • 2003 - 2007:     
    Chief Technology Officer, ViroNovative B.V. (0.1 fte), Rotterdam, NL
  • 2000 - 2004:     
    Fellow of the Royal Dutch Academy of Arts and Sciences (KNAW), NL
  • 1998 - present: 
    Senior scientist, dept. Viroscience, Erasmus MC Rotterdam, NL
  • 1995 - 1998:     
    Post-doc, Howard Hughes Medical Institute, University of Pennsylvania School of Medicine, dept. Microbiology, Philadelphia, PA, USA
  • 1990 - 1995:     
    PhD student, Dept. Clinical Viro-Immunology, CLB, University of Amsterdam, NL
  • 1988 -  1990:    
    Technician, Dept. Clinical Viro-Immunology, CLB, University of Amsterdam, NL


Publications

For more publications: Scopus

Scholarships, grants, and awards

  • Member of the Royal Dutch Academy of Arts and Sciences (2016)
  • Thomson Reuters Highly Cited Researcher (2014-present)
  • Member of the Royal Holland Society of Sciences and Humanities (2015)
  • Huibregtsenprijs for top innovative science with societal impact (2013)
  • Friedrich Loeffler lecture, Greifwald Germany (2012)
  • Elected Time Magazine “The 100 Most Influential People in the World” (2012)
  • Special recognition award from NIAID/NIH for extraordinary work on H1N1 influenza (2010)
  • NWO VICI laureate (2008)
  • Heine-Medin award of the European Society for Clinical Virology (2006)
  • Junior member of the Royal Dutch Academy of Arts and Sciences (Jonge Akademie)(2005)
  • James H. Nakano citation for outstanding scientific paper from NCID/CDC, USA (2003)
  • KNAW Fellowship (VIDI predecessor) (2000)

Research funding (current)

  • STW grant (oncolytic viro-immunotherapy)
  • EU Horizon 2020 program Delta-flu (molecular biology of avian influenza)
  • EU Horizon 2020 program VetBioNet (BSL3 infrastructure network)
  • US HHS/BARDA contract (antigenic drift, vaccines)
  • US NIH/NIAID contract “Center of Excellence for Influenza research” (influenza)
  • EU Horizon 2020 program Compare (next generation sequencing)
  • Support Casper grant (oncolytic viro-immunotherapy)

My Groups